ALX lays off 30% of staff to pay for more trials of CD47 blocker

ALX Oncology is laying off 30% of its workforce as the biotech seeks to channel its cash into further trials of its CD47 blocker.

The drug, called evorpacept, is in a pair of phase 2 trials for advanced head and neck squamous cell carcinoma.